FDA Peptide Vote Day 2: Semax, Epitalon Cleared. DSIP Didn't. What's Next?
FDA / PCAC — official records & coverage — FDA Peptide Vote Day 2: Semax, Epitalon Cleared. DSIP Didn't. What's Next?
Channel: Barrick Health · Our label: Government proceedings and coverage of them · Source: youtube.com/watch?v=5i5tTitWk9Y
What this video covers
Six of seven peptides cleared the FDA panel this week. BPC 157, KPV, TB 500, MOTS-c, Semax, and Epitalon. Now, here’s what headlines are getting wrong. Nothing is legal, not today and probably not this year.
Summary drawn from this video’s own transcript (banked in our research library, pulled 2026-11-07). Claims below are the speaker’s — attributed, not endorsed. This site publishes no dosing, protocol, or sourcing information.
Key points, in the speaker’s own framing
- BPC 157, KPV, TB 500, MOTS-c, Semax, and Epitalon.
- Should a compounding pharmacy be allowed to make this substance for a patient when a doctor prescribes it?
- Characterization, safety, evidence of effectiveness, and history of use in compounding.
- Thursday was BPC 157, KPV, TB 500, and MOTS-c.
- If your doctor writes for BPC-157 and a compounding pharmacy fills it, that was happening last month and it’ll happen next month.
- Back in April, these peptides came off a list the FDA keeps of substances it considers a safety risk.
Read next
- BPC-157 — compound page
- TB-500 — compound page
- MOTS-c — compound page
- Epitalon — compound page
- Semax — compound page
- KPV — compound page
- DSIP — more videos
- All videos from this channel
Educational information only — not medical advice. Peptides discussed on this page include substances that are not FDA-approved.